"Prepare a clinical paper on anti-inflammatory drugs...Planning to post next year"
2024-10-26 · ILIAS Biologics Inc. · original iliasbio.com ↗
ILB-202 Australian Phase 1 Blood Analysis Finds Drug Efficacy Patterns in Inflammatory Cells ILIAS Biologics also completed phase 1 clinical trial of IL-202, which was conducted in 18 healthy adults in November last year. Choi Dae-pyo said, "As a result of blood analysis, we have found a type (pattern) that can see the effectiveness of drugs in inflammatory cells and are preparing this as a thesis." ILIAS Biologics plans to analyze the contents by the end of this year and release them next year. Please check out the link below for more information. News Link PREV LIST NEXT Ilias Company name ILIAS Biologics Inc. CEO Chulhee Choi Corporate registration number 161-86-00309 ADDRESS 40-20 Techno 6-ro, Yuseong-gu, Daejeon, 34014, Republic of Korea TEL 042-863-4450 FAX 042-863-4499 ⓒ 2021 ILIAS Biologics Inc. ALL RIGHTS RESERVED.
The release as fetched from its publisher. iliasbio.com ↗